Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.
Hematopoietic stem cell transplantation (HSCT) and consolidation chemotherapy have been used to treat intermediate-risk acute myeloid leukemia (AML) patients in first complete remission (CR1). However, it is still unclear which treatments are most effective for these patients. The aim of our study w...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0132620 |
id |
doaj-c973c8c46a0b459f9917196beb51387c |
---|---|
record_format |
Article |
spelling |
doaj-c973c8c46a0b459f9917196beb51387c2021-03-03T20:00:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013262010.1371/journal.pone.0132620Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.Dandan LiLi WangHonghu ZhuLiping DouDaihong LiuLin FuCong MaXuebin MaYushi YaoLei ZhouQian WangLijun WangYu ZhaoYu JingLili WangYonghui LiLi YuHematopoietic stem cell transplantation (HSCT) and consolidation chemotherapy have been used to treat intermediate-risk acute myeloid leukemia (AML) patients in first complete remission (CR1). However, it is still unclear which treatments are most effective for these patients. The aim of our study was to analyze the relapse-free survival (RFS) and overall survival (OS) benefit of allogeneic HSCT (alloHSCT) for intermediate-risk AML patients in CR1. A meta-analysis of prospective trials comparing alloHSCT to non-alloHSCT (autologous HSCT [autoHSCT] and/or chemotherapy) was undertaken. We systematically searched PubMed, Embase, and the Cochrane Library though October 2014, using keywords and relative MeSH or Emtree terms, 'allogeneic'; 'acut*' and 'leukem*/aml/leukaem*/leucem*/leucaem*'; and 'nonlympho*' or 'myelo*'. A total of 7053 articles were accessed. The primary outcomes were RFS and OS, while the secondary outcomes were treatment-related mortality (TRM) and relapse rate (RR). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated for each outcome. The primary outcomes were RFS and OS, while the secondary outcomes were TRM and RR. We included 9 prospective controlled studies including 1950 adult patients. Patients with intermediate-risk AML in CR1 who received either alloHSCT or non-alloHSCT were considered eligible. AlloHSCT was found to be associated with significantly better RFS, OS, and RR than non-alloHSCT (HR, 0.684 [95% CI: 0.48, 0.95]; HR, 0.76 [95% CI: 0.61, 0.95]; and HR, 0.58 [95% CI: 0.45, 0.75], respectively). TRM was significantly higher following alloHSCT than non-alloHSCT (HR, 3.09 [95% CI: 1.38, 6.92]). However, subgroup analysis showed no OS benefit for alloHSCT over autoHSCT (HR, 0.99 [95% CI: 0.70, 1.39]). In conclusion, alloHSCT is associated with more favorable RFS, OS, and RR benefits (but not TRM outcomes) than non-alloHSCT generally, but does not have an OS advantage over autoHSCT specifically, in patients with intermediate-risk AML in CR1.https://doi.org/10.1371/journal.pone.0132620 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dandan Li Li Wang Honghu Zhu Liping Dou Daihong Liu Lin Fu Cong Ma Xuebin Ma Yushi Yao Lei Zhou Qian Wang Lijun Wang Yu Zhao Yu Jing Lili Wang Yonghui Li Li Yu |
spellingShingle |
Dandan Li Li Wang Honghu Zhu Liping Dou Daihong Liu Lin Fu Cong Ma Xuebin Ma Yushi Yao Lei Zhou Qian Wang Lijun Wang Yu Zhao Yu Jing Lili Wang Yonghui Li Li Yu Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS ONE |
author_facet |
Dandan Li Li Wang Honghu Zhu Liping Dou Daihong Liu Lin Fu Cong Ma Xuebin Ma Yushi Yao Lei Zhou Qian Wang Lijun Wang Yu Zhao Yu Jing Lili Wang Yonghui Li Li Yu |
author_sort |
Dandan Li |
title |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. |
title_short |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. |
title_full |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. |
title_fullStr |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. |
title_full_unstemmed |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. |
title_sort |
efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: a meta-analysis of prospective studies. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Hematopoietic stem cell transplantation (HSCT) and consolidation chemotherapy have been used to treat intermediate-risk acute myeloid leukemia (AML) patients in first complete remission (CR1). However, it is still unclear which treatments are most effective for these patients. The aim of our study was to analyze the relapse-free survival (RFS) and overall survival (OS) benefit of allogeneic HSCT (alloHSCT) for intermediate-risk AML patients in CR1. A meta-analysis of prospective trials comparing alloHSCT to non-alloHSCT (autologous HSCT [autoHSCT] and/or chemotherapy) was undertaken. We systematically searched PubMed, Embase, and the Cochrane Library though October 2014, using keywords and relative MeSH or Emtree terms, 'allogeneic'; 'acut*' and 'leukem*/aml/leukaem*/leucem*/leucaem*'; and 'nonlympho*' or 'myelo*'. A total of 7053 articles were accessed. The primary outcomes were RFS and OS, while the secondary outcomes were treatment-related mortality (TRM) and relapse rate (RR). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated for each outcome. The primary outcomes were RFS and OS, while the secondary outcomes were TRM and RR. We included 9 prospective controlled studies including 1950 adult patients. Patients with intermediate-risk AML in CR1 who received either alloHSCT or non-alloHSCT were considered eligible. AlloHSCT was found to be associated with significantly better RFS, OS, and RR than non-alloHSCT (HR, 0.684 [95% CI: 0.48, 0.95]; HR, 0.76 [95% CI: 0.61, 0.95]; and HR, 0.58 [95% CI: 0.45, 0.75], respectively). TRM was significantly higher following alloHSCT than non-alloHSCT (HR, 3.09 [95% CI: 1.38, 6.92]). However, subgroup analysis showed no OS benefit for alloHSCT over autoHSCT (HR, 0.99 [95% CI: 0.70, 1.39]). In conclusion, alloHSCT is associated with more favorable RFS, OS, and RR benefits (but not TRM outcomes) than non-alloHSCT generally, but does not have an OS advantage over autoHSCT specifically, in patients with intermediate-risk AML in CR1. |
url |
https://doi.org/10.1371/journal.pone.0132620 |
work_keys_str_mv |
AT dandanli efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT liwang efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT honghuzhu efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT lipingdou efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT daihongliu efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT linfu efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT congma efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT xuebinma efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT yushiyao efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT leizhou efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT qianwang efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT lijunwang efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT yuzhao efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT yujing efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT liliwang efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT yonghuili efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies AT liyu efficacyofallogeneichematopoieticstemcelltransplantationinintermediateriskacutemyeloidleukemiaadultpatientsinfirstcompleteremissionametaanalysisofprospectivestudies |
_version_ |
1714824618745790464 |